Drugs / IBI3002
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07015762 | Jul 2025 → May 2026 overdue | atopic eczema | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1 | NCT07015749 | Jun 2025 → May 2026 overdue | asthma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1 | NCT06947408 | May 2025 → May 2026 | asthma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06213844 | Feb 2024 → Jul 2025 | asthma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07399067 | Feb 2026 → Mar 2027 expected | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences innoventbio.com ↗
In the single-dose study, IBI3002 exhibited favorable safety and tolerability among participants with mild-to-moderate asthma, alongside improvements in multiple pharmacodynamic and pulmonary function endpoints. |
| 2025-05-15 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent to Present New Preclinical Data on Novel Bispecific Antibody IBI3002 (IL-4Rα/TSLP) for Asthma Treatment at ATS 2025 innoventbio.com ↗
Preclinical data have shown that IBI3002 effectively targets and inhibits the IL-4Rα and TSLP pathways, and its TSLP inhibitory activity is stronger than that of Tezepelumab, a benchmark monoclonal antibody approved for asthma. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences innoventbio.com ↗ |
| 2025-05-15 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent to Present New Preclinical Data on Novel Bispecific Antibody IBI3002 (IL-4Rα/TSLP) for Asthma Treatment at ATS 2025 innoventbio.com ↗ |
| 2024-03-01 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06213844 ↗ |
| Route | Subcutaneous | “administered subcutaneously on Day 1” NCT06213844 ↗ |